TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06015516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minoxidil Tablets
Description: Since oral minoxidil is a new formulation and, according to the recommendations of the Regulatory Authorities, it is considered appropriate to carry out a multiple dose study to evaluate and to compare the bioavailability between both formulations (oral versus topical solution), measuring the plasma concentrations of minoxidil.~Achievement of steady-state is assessed by comparing at least three pre-dose concentrations for each formulation, as half-life of minoxidil is around 4 hours, we will administered 5 doses in each period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil topical solution 20 mg/ml
Description: Since oral minoxidil is a new formulation and, according to the recommendations of the Regulatory Authorities, it is considered appropriate to carry out a multiple dose study to evaluate and to compare the bioavailability between both formulations (oral versus topical solution), measuring the plasma concentrations of minoxidil.~Achievement of steady-state is assessed by comparing at least three pre-dose concentrations for each formulation, as half-life of minoxidil is around 4 hours, we will administered 5 doses in each period.
Study: NCT06642194

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education on sunnah of sleeping
Description: The interventions had three session which conducted between 40-60 minutes per session. The session include: 1) introducing the research objectives, definition and benefits on sunnah of sleeping; 2) steps in sunnah of sleeping (early bedtime and early wake up time; perform ablution (wudoo) before going to bed and supplicate; dusting and cleaning the bed before sleeping; sleep position; turning off light before sleep; cover mouth when yawning and reciting some verses such as Ayat Kursi, Al-Ikhlas, Al-Falq and An-Nas); 3) providing mp3 and prayers beads to facilitate Qur'an recitation and zikr. These surat was chosen because the portion of surat concentrate on the absolute divinity of Allah and Allah's blessings to His creatures. The surat brings every Muslim the closeness to Allah, the calmness of the soul, and the cure for many physical and psychological diseases. The steps in sunnah of sleeping can be performed approximately about 10-15 minutes about 30 minutes prior to sleep.
Study: NCT06564038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0486
Description: AZD0486 will be administered as either SC injection (substudies 1 and 2) or IV infusion (substudy 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0486
Description: AZD0486 will be administered as either SC injection (substudies 1 and 2) or IV infusion (substudy 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0486
Description: AZD0486 will be administered as either SC injection (substudies 1 and 2) or IV infusion (substudy 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0486
Description: AZD0486 will be administered as either SC injection (substudies 1 and 2) or IV infusion (substudy 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0486
Description: AZD0486 will be administered as either SC injection (substudies 1 and 2) or IV infusion (substudy 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib tablet will be administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib tablet will be administered orally twice daily.
Study: NCT06402630

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants are block randomised to be treated with 0.25%, 0.5%, 1.0%, 2% STS-01 or a matching placebo control topically once daily for 6 months with a 2-month follow up.
Study: NCT06055075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forimtamig
Description: Forimtamig will be administered SC at different doses during dose exploration phase. Forimtamig will be administered at a fixed dose determined during dose exploration phase in dose expansion phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forimtamig
Description: Forimtamig will be administered SC at different doses during dose exploration phase. Forimtamig will be administered at a fixed dose determined during dose exploration phase in dose expansion phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forimtamig
Description: Forimtamig will be administered SC at different doses during dose exploration phase. Forimtamig will be administered at a fixed dose determined during dose exploration phase in dose expansion phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forimtamig
Description: Forimtamig will be administered SC at different doses during dose exploration phase. Forimtamig will be administered at a fixed dose determined during dose exploration phase in dose expansion phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forimtamig
Description: Forimtamig will be administered SC at different doses during dose exploration phase. Forimtamig will be administered at a fixed dose determined during dose exploration phase in dose expansion phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forimtamig
Description: Forimtamig will be administered SC at different doses during dose exploration phase. Forimtamig will be administered at a fixed dose determined during dose exploration phase in dose expansion phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forimtamig
Description: Forimtamig will be administered SC at different doses during dose exploration phase. Forimtamig will be administered at a fixed dose determined during dose exploration phase in dose expansion phase.
Study: NCT05407818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63733657
Description: JNJ-63733657 will be administered as an IV infusion.
Study: NCT06055075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered via IV infusion in combination with forimtamig.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered via IV infusion in combination with forimtamig.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered via IV infusion in combination with forimtamig.
Study: NCT05049668

Intervention type: DRUG
Intervention: ATGAM plus CsA with or without Eltrombopag
Description: Standard treatment with or without Eltrombopag
Study: NCT05193409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225 mg BNC210
Description: 225 mg BNC210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 675 mg BNC210
Description: 675 mg BNC210

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06564038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered either oral or IV infusion as per standard of care.
Study: NCT06055075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered via IV infusion in combination with forimtamig.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered via SC injection in combination with forimtamig.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered via SC injection in combination with forimtamig.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered via SC injection in combination with forimtamig.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered via SC injection in combination with forimtamig.
Study: NCT04199182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: A multi-component group exercise intervention that emphasizes functional training. Duration is 6 months, and frequency is 3x per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Aging Attention Control (HA-ATC)
Description: Participants in the HA-ATC group will receive a health education program modeled on the 10 Keys to Healthy Aging curriculum and the National Council on Aging's Aging Mastery Program. HA-ATC will include an 8-week face-to-face group program followed by bi-weekly sessions for the remaining 4 months.
Study: NCT05647057

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: A: gelofusine + ringers
Description: 750 milliliter (mL) modified fluid gelatin (Braun Melsungen, Germany), 650 mL Ringer's solution (Baxter, Utrecht, Netherlands) and 100 mL mannitol (15%, Baxter, Utrecht, Netherlands)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: B: albumine + ringers
Description: 200 mL human albumin (20%, Sanquin, Amsterdam, Netherlands), 1200 mL Ringer's solution (Baxter, Utrecht, Netherlands) and 100 mL mannitol (15%, Baxter, Utrecht, Netherlands)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: C: ringers + retrograde autologous priming
Description: 1400 mL Ringer's solution (Baxter, Utrecht, Netherlands) and 100 mL mannitol (15%, Baxter, Utrecht, Netherlands) with retrograde autologous priming.~Retrograde autologous priming (RAP) is applied using clinical parameters such as Central Venous Pressure, Mean Arterial Pressure (MAP), and intra cardiac filling pressure based on Trans Esophageal Echo as guidance to the amount of fluid displaced. RAP is applied to a maximum volume of 475 mL provided that systolic blood pressure will remain \>90 millimeter of mercury (mmHg). Phenylephrine can be administered up to 200 mcg to keep the system hemodynamics stable during RAP. In case of a body surface area \<1.7m2, a maximum volume of 375 mL is desired. Once the desired amount of prime is displaced, the transfusion bag is clamped and CPB is started. If additional fluids are needed during CPB to maintain optimal perfusion, the displaced prime is used prior to the vasoplegia protocol.
Study: NCT05117450

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Decrease per-dialytic heparin therapy
Description: Decrease per-dialytic heparin therapy with the HYDROLINK membrane (dialyzer NV-21U, surface 2.1m², Toray industry, Tokyo, Japan) and with the HeprAN membrane (dialyzer Evodial 2.2, surface 2.15 m2, Hospal SAS, Meyzieu, France)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Decrease per-dialytic heparin therapy
Description: Decrease per-dialytic heparin therapy with the HYDROLINK membrane (dialyzer NV-21U, surface 2.1m², Toray industry, Tokyo, Japan) and with the HeprAN membrane (dialyzer Evodial 2.2, surface 2.15 m2, Hospal SAS, Meyzieu, France)
Study: NCT05096117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8062
Description: ASP8062 is a novel compound with positive allosteric modulator (PAM) activity on the γ-aminobutyric acid type B (GABAB) receptor, 25 mg, 1 x per day for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 x per day for 6 weeks
Study: NCT05376488

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One meal
Description: One meal given to assess impact on ammonia levels serially

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One meal
Description: One meal given to assess impact on ammonia levels serially

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One meal
Description: One meal given to assess impact on ammonia levels serially
Study: NCT06000969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung Recruitment Conventional
Description: the recruitment maneuver will be performed by manual inflation with a pressure of 30 cmH2O for 30 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung Recruitment Ultrasound
Description: the recruitment maneuver will be performed under the direct real-time guidance of ultrasound if atelectasis (defined as LUS of ≥ 2 for any of the 12 regions) is present. This will be done by manual inflation with a pressure of 10 cmH2O for 10 seconds, increased 10 cmH2O every 10 seconds until no collapsed areas are visible on the ultrasound, the maximum airway pressure will be limited to 40 cmH2O. This could be repeated if needed.
Study: NCT05618652

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Equity Focused and Trauma-Informed Communication Intervention
Description: Clinician communication intervention that includes didactic training and real-time feedback on communication behaviors during clinical encounters.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Equity Focused and Trauma-Informed Communication Intervention
Description: Clinician communication intervention that includes didactic training and real-time feedback on communication behaviors during clinical encounters.
Study: NCT04222270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Champion Caregiver peer mentoring support to caregivers on child care and medication adherence to enhance achievement of viral suppression
Description: Caregiver to caregiver peer support intervention through group/one-on-one education and counselling
Study: NCT06033300

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sample
Study: NCT05202080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid Counseling and Pain Coping Skills Video
Description: The intervention will be in the form of a video of a PowerPoint presentation with instructions and exercises designed to coach patients about catastrophizing, coping skills, mindfulness and behavioral modification techniques, in addition to providing education regarding postoperative analgesia and opioid use.
Study: NCT05797545

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breast MRI for Breast Cancer Detection
Description: Comparison of diagnostic results of abbreviated breast MRI and full protocol MRI for secondary breast cancer surveillance

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breast MRI for Breast Cancer Detection
Description: Comparison of diagnostic results of abbreviated breast MRI and full protocol MRI for secondary breast cancer surveillance
Study: NCT06564038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered as IV infusion as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as IV infusion as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine will be administered as IV infusion as per standard of care.
Study: NCT05917717

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuroprotective 'bundle of care'
Description: This includes the 3 devices:~* Head up cardiopulmonary resuscitation (HUP-CPR)~* Active compression decompression CPR~* Impedance threshold device (ITD)
Study: NCT06564038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered as IV infusion as per standard of care.
Study: NCT05843604

Intervention type: OTHER
Intervention: Functional MRI
Description: Three cognitive tests will be performed in the MRI, namely a stroop task, an N-back task and a switching task
Study: NCT05630755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOR/ISL
Description: DOR/ISL 100 mg/0.25 mg oral tablets once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIC/FTC/TAF
Description: BIC/FTC/TAF 50 mg/200 mg/25 mg oral tablets once daily
Study: NCT05391126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Usual dosing per package insert.
Study: NCT06555965

Intervention type: OTHER
Intervention: Non-interventional study
Description: There is no planned intervention in this study

Intervention type: OTHER
Intervention: Non-interventional study
Description: There is no planned intervention in this study
Study: NCT06322342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVP-001
Description: MRI contrast agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVP-001
Description: MRI contrast agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVP-001
Description: MRI contrast agent
Study: NCT05231122

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD40 Agonist Monoclonal Antibody CDX-1140
Description: Given IV
Study: NCT05630755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BIC/FTC/TAF
Description: 0 mg oral tablets once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to DOR/ISL
Description: 0 mg oral tablets once daily
Study: NCT06288009

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Running locking suture
Description: In running locking sutures, the first anchoring knot is made at one end of the wound, and a loop of suture is left from the beginning of the throw. The needle is then passed through the loop of suture, locking the suture in place. This is repeated until reaching the end of the wound, where the suture material is then tied to the loop using an instrument tie for the final throw.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Running locking suture
Description: In running locking sutures, the first anchoring knot is made at one end of the wound, and a loop of suture is left from the beginning of the throw. The needle is then passed through the loop of suture, locking the suture in place. This is repeated until reaching the end of the wound, where the suture material is then tied to the loop using an instrument tie for the final throw.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard running suture
Description: In standard running sutures, the first anchoring knot is made at one end of the wound, and all of the suture material is pulled through after completing the throw. This is repeated until reaching the end of the wound, where the suture material is then tied.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard running suture
Description: In standard running sutures, the first anchoring knot is made at one end of the wound, and all of the suture material is pulled through after completing the throw. This is repeated until reaching the end of the wound, where the suture material is then tied.
Study: NCT05775354

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Early diagnosis strategy
Description: RED-CVD early diagnosis questionnaire, physical examination, laboratory testing, electrocardiography, echocardiography
Study: NCT05914376

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human IL-21-expressing oncolytic vaccinia virus injection
Description: hV01 is a recombinant vaccinia virus with deletions of the viral thymidine kinase (TK) and viral growth factor (VGF) genes and insertion of the human IL-21 gene.
Study: NCT05015530

Intervention type: DEVICE
Intervention: Healsea® Chronic, hypertonic seawater-based nasal spray supplemented with natural Symbiofilm® extract
Description: Healsea® Chronic nasal spray will be administered twice daily (1 puff, 1-2 sec) in each nostril during 30 days
Study: NCT06046833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre 3 continuous glucose monitoring sensor
Description: The Freestyle Libre 3 sensor is a small real-time continuous glucose monitor device that measures glucose levels every minute

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FreeStyle Libre 3 continuous glucose monitoring sensor
Description: The Freestyle Libre 3 sensor is a small real-time continuous glucose monitor device that measures glucose levels every minute

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional drink
Description: Balanced nutritional drink (Boost plus 8 ounces/237 mL)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional drink
Description: Balanced nutritional drink (Boost plus 8 ounces/237 mL)
Study: NCT05901311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537982
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]-LY3537982
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]-LY3537982
Description: Administered IV.
Study: NCT04779697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 analogue - semaglutide
Description: GLP-1 analogue - semaglutide - administered once weekly for a total of 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - administered once weekly for a total of 12 weeks
Study: NCT06359379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropidoxuridine
Description: Ropidoxuridine is administered daily, 5 days a week, for 7 weeks, starting one week prior to radiotherapy, and then concurrently with a standard 60 Gy radiotherapy, followed by a 4-week rest period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropidoxuridine
Description: Ropidoxuridine is administered daily, 5 days a week, for 7 weeks, starting one week prior to radiotherapy, and then concurrently with a standard 60 Gy radiotherapy, followed by a 4-week rest period.
Study: NCT05233293

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spyglass + RFA
Description: SpyGlass direct Vision guided RFA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cytobrush + RFA
Description: After Cytobrush ,taking RFA through ERCP